Skip to main content
. Author manuscript; available in PMC: 2011 May 13.
Published in final edited form as: J Cell Biochem. 2010 May;110(1):171–181. doi: 10.1002/jcb.22523

Fig. 1.

Fig. 1

Cell viability of human pancreatic cancer (PC) cell lines treated with B-DIM, erlotinib (Erl), gemcitabine (Gem), and the combination evaluated by the MTT assay. AsPC-1, BxPC-3, COLO-357, L3.6pl, HPAC, MIA PaCa-2, and PANC-1 cells were treated with B-DIM (25 μM), erlotinib (2 μM), gemcitabine (10 nM), and the combination. There was a significant reduction in cell growth in the BxPC-3, COLO-357, and HPAC cells treated with B-DIM in combination with either erlotinib or gemcitabine or triple combination compared to cells treated with single agents. A trend for potentiation of growth inhibition by B-DIM was observed in L3.6pl cells when combined with erlotinib or gemcitabine, but no such potentiation was observed in AsPC-1, MIA PaCa-2, and PANC-1 cells.